Mega Lifesciences Public Company Limited (MEGA-R.BK)
Full history for every metric is available with a Kvantra account
Mega Lifesciences Public Company Limited (MEGA-R.BK)
No price history available.
Key financial summary
Financials in THB| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | THB bn | 13 | 14 | 16 | 16 | 15 | 14 | 14 | 15 |
| Operating profit | THB bn | 3 | 3 | ||||||
| Net profit | THB bn | 1 | 2 | 2 | 2 | 2 | 2 | 2 | 2 |
| EPS reported | THB | 2.19 | 2.51 | ||||||
| Operating cashflow per share | THB | 3.22 | 3.53 | ||||||
| Capex per share | THB | 0.76 | 0.56 | ||||||
| FCF per share | THB | 2.46 | 2.97 | ||||||
| Free cash flow | THB bn | 2 | 2 | ||||||
| Net debt | THB bn | -4 | -4 | ||||||
| Book value equity | THB bn | 10 | 10 | ||||||
| Book value per share | THB | 11.72 | 11.86 | ||||||
| Number of shares | m | 871.87 | 871.87 | ||||||
| DPS (TTM paid) | THB | 1.60 | 1.65 |
Financial summary
Financials in THB| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | 15.30 | 14.66 | ||||||
| P/B LTM | x | 2.86 | 2.82 | ||||||
| P/S LTM | x | 2.06 | 2.02 | ||||||
| P/FCF LTM | x | 13.63 | 13.02 | ||||||
| EV/EBITDA LTM | x | 9.34 | 8.31 | ||||||
| EV/Sales LTM | x | 1.81 | 2.04 | ||||||
| Earnings Yield LTM | % | +6.54% | +6.82% | ||||||
| FCF Yield | % | +7.34% | +7.68% | ||||||
| Quality | |||||||||
| ROE | % | +18.72% | +20.49% | ||||||
| ROIC | % | +20.18% | +20.09% | ||||||
| Operating margin | % | +20.52% | +21.10% | ||||||
| Gross margin | % | +51.37% | +52.23% | ||||||
| FCF/Sales | % | +15.15% | +18.05% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | -5.19% | +8.66% | ||||||
| Sales Growth YoY | % | -7.80% | -5.61% | ||||||
| Net Income Growth YoY | % | -4.99% | +8.84% | ||||||
| FCF Growth | % | -0.04% | +4.67% | ||||||
| Operating Profit Growth | % | -13.87% | -10.11% | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | +4.78% | +4.24% | ||||||
| Dividend Growth | % | 0.00% | +3.12% | ||||||
| Payout Ratio | % | +73.06% | +67.67% | ||||||
| FCF/Debt | x | 3.14 | 3.23 | ||||||
| Net Debt/EBITDA | x | -1.31 | -1.21 | ||||||
| EBIT/Net interest | x | 52.70 | 49.69 | ||||||
| Net debt/market cap | % | +1.62% | +1.45% | ||||||
| Net debt/Equity | x | -0.41 | -0.34 | ||||||
| Gross debt/equity | x | 0.07 | 0.07 | ||||||
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
Company overview
Mega Lifesciences Public Company Limited, a subsidiary of Unistretch Limited, was founded in 1982 and is based in Bangkok, Thailand. This diversified healthcare enterprise is primarily involved in the production, promotion, and sale of an extensive array of health-related products, encompassing dietary supplements, over-the-counter (OTC) and prescription pharmaceuticals, herbal remedies, vitamins, and fast-moving consumer goods. The company organizes its activities across three main divisions: Brands, Distribution, and Original Equipment Manufacture (OEM). Its vast product portfolio includes a wide selection of complementary medicines designed for various needs, such as bone and joint support, children's health, diabetes and heart care, herbal solutions, liver and digestive well-being, skin health, weight management, overall vitality, specific men's and women's health products, and sports nutrition. Additionally, the pharmaceutical segment provides OTC solutions for gastrointestinal issues and pain, alongside a comprehensive range of prescription drugs targeting therapeutic areas like iron deficiency, anticoagulation, diabetology, cardiology, dermatology, gastroenterology, neurology, pain management, osteoporosis, respiratory conditions, urology, oncology, and nephrology. Beyond its core product lines, Mega Lifesciences offers logistical and marketing services for goods manufactured by other companies. It also operates wellness centers and engages in software design, development, and related service provisions. The company maintains a strong global footprint, with operations spanning the Asia Pacific, the Middle East, Africa, and the Commonwealth of Independent States regions.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Mega Lifesciences Public Company Limited (MEGA-R.BK)
No price history available.
Based on consensus from external analysts. Not Kvantra's opinion.
Mega Lifesciences Public Company Limited, a subsidiary of Unistretch Limited, was founded in 1982 and is based in Bangkok, Thailand. This diversified healthcare enterprise is primarily involved in the production, promotion, and sale of an extensive array of health-related products, encompassing dietary supplements, over-the-counter (OTC) and prescription pharmaceuticals, herbal remedies, vitamins, and fast-moving consumer goods. The company organizes its activities across three main divisions: Brands, Distribution, and Original Equipment Manufacture (OEM). Its vast product portfolio includes a wide selection of complementary medicines designed for various needs, such as bone and joint support, children's health, diabetes and heart care, herbal solutions, liver and digestive well-being, skin health, weight management, overall vitality, specific men's and women's health products, and sports nutrition. Additionally, the pharmaceutical segment provides OTC solutions for gastrointestinal issues and pain, alongside a comprehensive range of prescription drugs targeting therapeutic areas like iron deficiency, anticoagulation, diabetology, cardiology, dermatology, gastroenterology, neurology, pain management, osteoporosis, respiratory conditions, urology, oncology, and nephrology. Beyond its core product lines, Mega Lifesciences offers logistical and marketing services for goods manufactured by other companies. It also operates wellness centers and engages in software design, development, and related service provisions. The company maintains a strong global footprint, with operations spanning the Asia Pacific, the Middle East, Africa, and the Commonwealth of Independent States regions.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free